ANI PHARMACEUTICALS, INC (ANIP): what the price assumes

boothcheck covers ANI PHARMACEUTICALS, INC (ANIP) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/ANIP

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7.7% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is supported by earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.0%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• The mix is changing under the reported numbers: generics remain the largest revenue line at 43%, while Cortrophin Gel at 39% grew 42.1% in the first quarter of 2026.
• Growth is being rented rather than owned, with the share count rising about 7.5% a year over the past four years and the FY2025 10-K describing a $325.0 million term loan drawn in September 2024 to finance the Alimera acquisition.
• Payer policy is the swing variable, and the 10-K names state Prescription Drug Affordability Boards asserting authority to set reimbursement rates as one of the pressures already in motion.

Bull Case

Calling this a growth-stage company is accurate and slightly misleading at the same time. The right way to read the income statement is not as one business with a growth rate but as a portfolio of product curves running at different speeds. Generic pharmaceutical products, still the largest single line at 43% of revenue, grew 6.8% in the first quarter of 2026. Cortrophin Gel, at 39%, grew 42.1% over the same period, and the whole company grew 20.5%. A blended growth rate averages away the only thing that matters here, which is that the fast line and the slow line are trading places.

That matters because the two lines carry different economics, and the peer cohorts show it plainly. In generics, Amneal (AMRX) converts 14.3% of revenue into operating income and Teva (TEVA) 16.2%, on their own filed figures. In rare disease and specialty brands, Catalyst Pharmaceuticals (CPRX) posts 44.8% and Harmony Biosciences (HRMY) 21.1%. ANI currently earns 13.2%, which is a generics margin. The bull case is arithmetic on the mix: as the specialty share of revenue rises, the whole company's margin has somewhere structurally higher to travel toward.

The generic base is not dead weight in that story, and management does not treat it as such. The 10-K describes a plan to strengthen the segment "through continued investment in our research and development capabilities and increased focus on niche opportunities", which is the sensible version of the strategy: not chasing volume in commodity molecules, but picking products where few competitors bother to file. A generics book run that way throws off cash without demanding much of it, and cash is what funds a specialty launch.

Cortrophin Gel is the asset carrying the thesis, and its trajectory has been steep enough that the licensing arrangement underneath it has moved through its tiers. The 10-K notes that 2025 revenues surpassed the highest royalty tier for incremental net sales, which is an unusual sort of complaint to have. The company has also secured FDA clearance for a prefilled syringe presentation, which removes a step from the patient's side of the transaction and is exactly the kind of unglamorous change that widens a prescriber base.

Financially the company is not stretched. Cash and investments roughly offset the borrowings on a funded-debt basis, operating income covers the interest bill 3.6 times, and the board has authorized a $100 million share repurchase program. Management has also raised its own guidance twenty times and reaffirmed it thirteen times since 2009. That is not a company that has made a habit of promising more than it delivers.

Bear Case

The variable with the most leverage over this thesis is not sales execution. It is who decides the price. ANI sells injectable specialty products whose revenue depends on government and commercial reimbursement, and the FY2025 10-K sets out an unusually crowded regulatory picture: executive orders on drug pricing, manufacturers reaching agreements with the federal government on Medicaid and newly launched product prices, and states forming Prescription Drug Affordability Boards "that assert the authority to set reimbursement rates and/or drug pricing in the state". The filing also warns that non-compliance with the Medicaid Drug Rebate Program and other government pricing programs can trigger penalties and sanctions. None of that shows up in a growth rate until it does, all at once.

Underneath the reported revenue sits a royalty stack that gets heavier as the business succeeds. The 10-K discloses a blended Merck royalty on Cortrophin Gel of approximately 10% across 2023 through 2025, and states that because 2025 revenues passed the highest tier, the blended rate will increase as revenues rise. On the ophthalmic products, the company owes EyePoint 30% of annual U.S. net sales above thresholds that began at seventy million dollars in 2025 and step up each year through 2028. Incremental dollars from the two fastest-growing lines are therefore worth measurably less than the average dollar already in the P&L.

The capital structure is the third pressure. Growth here has been bought, not generated: the share count has risen roughly 7.5% a year over four years, and the September 2024 Alimera transaction was financed with a $325.0 million term loan secured, per the 10-K, by substantially all of the company's assets. Interest is covered 3.6 times, which is adequate rather than comfortable, and the funded-debt position nets out to roughly nothing once cash and investments are counted against borrowings. A specialty pharma with no net cash cushion has less room to absorb a reimbursement shock than its growth rate implies.

Litigation adds a live item. On July 16, 2026 a Delaware judge denied the company's post-trial motions in its dispute with CG Oncology, and ANI has said it intends to appeal to the Delaware Supreme Court while seeking to recover the value of assets it sold, including a 5% running royalty on future worldwide sales. Appeals are slow and their outcomes are not forecastable from financial statements.

Put together, the bear case here is not that the stock is dear. Roughly fifteen times operating income for a business still adding revenue at a double-digit clip is not a demanding price, and the market has already built in a mild decline in operating profit rather than growth. The argument is about whether today's operating profit is a base or a peak: rising royalty rates on the growth products, commodity pricing on the largest line, a share count that keeps expanding, and a policy environment where the buyer sets the price. Each of those pushes the same direction, and none of them requires a product to fail.

Valuation

A price that assumes decline sits on top of a business posting double-digit revenue growth. That is the whole valuation question in one sentence. At $77.61 the market is paying roughly fifteen times company-wide operating income, and inverted, that multiple embeds operating profit shrinking about 2.5% a year over the next five years. First-quarter revenue rose 20.5%. Those two facts have to be reconciled by something, and the something is the market's view of durability rather than of arithmetic.

The methods used to triangulate mostly land above the price. Peer multiples land well above, the cash-flow projections land well above, and the earnings-power lenses land essentially on it. Only the asset-based methods land below, which is what happens when a balance sheet carries a large slug of acquired intangibles from a recent purchase: book value flatters nothing, and methods that lean on it produce a low number by construction. The pattern is a value read with an asset-quality asterisk, not a growth premium.

The concrete requirement is unusually forgiving. Nothing in the price asks for margin improvement at all, and it would tolerate a slow slide in profitability from here. What it will not tolerate is the royalty and pricing pressures compounding faster than the mix shift can offset them, because the reported margin is the product of a tug of war between a growing specialty book and a generics book that competes on price.

Cohort position explains why the multiple sits where it does. On operating margin ANI's 13.2% sits close to AMRX at 14.3% and TEVA at 16.2%, the generic manufacturers, and nowhere near CPRX at 44.8% or HRMY at 21.1% in rare disease. The multiple is in the lower half of the peer range as well. The market, in other words, is currently valuing the company as the thing 43% of its revenue still is, rather than as the thing 39% of its revenue is becoming. Whether that is a mistake or a fair discount for execution risk is the actual investment question.

The balance sheet neither rescues nor endangers the case. On the funded-debt measure, borrowings are very nearly matched by cash and investments, so leverage is not the immediate issue; interest coverage of 3.6 times is the number that would tighten first if profit slipped. The item that deserves more attention than leverage is the share count, which has climbed about 7.5% a year for four years. Per-share growth has been running well behind company growth, and closing that gap is what the newly authorized repurchase program is for.

Catalysts

First-quarter results, reported May 8, 2026, were the strongest print in the company's recent sequence: net revenues of $237.5 million, up 20.5% on the year, with Cortrophin Gel contributing $75.1 million, up 42.1%, and the generics business $105.4 million, up 6.8%. Net income available to common shareholders was $29.5 million and diluted earnings per share on a reported basis were $1.28. Management raised full-year 2026 revenue guidance to a range of $1,080 million to $1,140 million with the same release.

Alongside the raise, the board authorized a $100 million share repurchase program. That is a notable turn for a company whose share count has been expanding rather than contracting, and it is the first mechanism management has put in place to convert company-level growth into per-share growth. Whether it gets used, and at what pace, is worth tracking through the next two reports.

The open legal item moved in July. On July 16, 2026 a Delaware judge denied ANI's post-trial motions for a new trial and for judgment as a matter of law in the CG Oncology matter, and the company announced its intent to appeal to the Delaware Supreme Court while seeking to recover the value of the assets it sold, including a 5% running royalty on future worldwide sales. Separately, FDA clearance of a prefilled syringe presentation for Cortrophin Gel removes friction at the point of administration, which matters more for a physician-administered injectable than a product headline usually suggests.

Peer Cohorts (Per Segment, With Filing Citations)

Generics and Other (reported)

• AMRX (AMNEAL PHARMACEUTICALS, INC.)
• FY2025 10-K: …labeled versions of pharmaceutical products introduced by brand companies (directly or through a third-party) under the brand's NDA, have also increased competition in the generic pharmaceutical industry. Authorized generic pharmaceutical products may be sold prior to, during and subsequent to the 180-day exclusivity…
• FY2025 10-K: 3, Amneal Pharmaceuticals LLC ("Amneal") received a Civil Investigative Demand ("CID") from the Civil Division of the United States Department of Justice (the "Civil Division") requesting information and documents related to the manufacturing and shipping of diclofenac sodium 1 % gel labeled as "prescription only"…
• TEVA (TEVA PHARMACEUTICAL INDUSTRIES LIMITED)
• FY2025 10-K: …towards growth engines and innovation. Generic Medicines Generic medicines are the chemical and therapeutic equivalents of originator medicines and are typically more affordable in comparison to the originator's products. Generic medicines are required to meet similar governmental requirements as their brand-name…
• FY2025 10-K: …of our net sales from our major customers, see note 19 to our consolidated financial statements. Our revenues and profits from generic products may decline as a result of competition from other pharmaceutical companies and changes in regulatory policy. Our generic products face intense competition. Prices of generic…
• VTRS (Viatris Inc)
• FY2025 10-K: …products. Additionally, pricing is often affected by factors outside of the Company's control. Conversely, generic products generally experience less volatility over a longer period of time in Europe as compared to the U.S., primarily due to the role of government oversight of healthcare systems in the region. In…
• FY2025 10-K: …their own authorized generic product prior to or at the same time or after generic competition initially enters the market; • pricing a branded product at a discount equivalent to generic pricing; • filing frivolous petitions with the FDA or other regulatory bodies seeking to prevent or delay approvals, including…
• PRGO (Perrigo Company plc)
• FY2025 10-K: …and consumer product companies, such as Haleon, Kenvue, Procter & Gamble, Reckitt Benckiser, Abbott Nutrition, Bayer AG, Opella, Philips, Teva, Viatris, and Stada. Each product category of our business has certain key competitors, such that a competitor generally does not compete across all product lines or across…
• FY2025 10-K: …year 2010. Refer to Item 8. Note 20 . While we intend to defend these lawsuits vigorously, any adverse decision could have a material adverse impact on our business, results of operations and reputation. In addition, in May 2018, Perrigo was also served with and responded to a civil investigative demand in connection…

Rare Disease and Brands (reported)

• CPRX (CATALYST PHARMACEUTICALS, INC.)
• FY2025 10-K: 80 mg to 100 mg. We believe that this most recent sNDA approval offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS. We are also planning to evaluate FIRDAPSE® in the future for the treatment of other diseases. We sell FIRDAPSE® in the U.S. through a…
• FY2025 10-K: …and specifically the commercialization of FIRDAPSE® and any other products we develop. While it is difficult to quantify in the absence of specific proposals, we assess the risk of a material financial impact from potential new tariffs to be low due to a significant portion of our supply chain being U.S. based;…
• SUPN (SUPERNUS PHARMACEUTICALS, INC.)
• FY2025 10-K: …litigation, pressure from new or existing competitive products, or adverse changes in coverage under managed care programs, the adverse impact on our revenue and profit could be significant. For example, in November 2025 we announced that supplier constraints were impacting our ability to fully meet demand for ONAPGO…
• FY2025 10-K: …sales and marketing resources in the U.S., we continue to drive the revenue growth of our key marketed products. • Advance product candidates toward commercialization. Several product candidates are in various stages of development. • Continue to grow our pipeline. We continue to evaluate and develop additional CNS…
• HRMY (HARMONY BIOSCIENCES HOLDINGS, INC.)
• FY2025 10-K: …diseases segment consists of the Company's commercial product, WAKIX, and its potential product candidates, that focus on patients living with rare neurological diseases who have unmet needs. The Company currently derives all of its revenue from sales of WAKIX, which is used in the treatment of EDS and cataplexy in…
• FY2025 10-K: …rare pediatric disease; ● the product contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in another marketing application; ● the application does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug…
• TVTX (TRAVERE THERAPEUTICS, INC.)
• FY2025 10-K: …receive marketing approval, that we or a collaboration partner bring to the market may not gain market acceptance by physicians, patients, third-party payers, and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and we…
• FY2025 10-K: …in manufacturing scale-up to support initial commercial scale manufacturing as well as full enrollment in the HARMONY Study. Following further optimization of the manufacturing process in 2025, we restarted enrollment activities for the pivotal Phase 3 HARMONY Study in the first quarter of 2026. In addition, we…
• KNSA (Kiniksa Pharmaceuticals International, plc)
• FY2025 10-K: …recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and…
• FY2025 10-K: …FDA to reconsider the BLA. If and when the deficiencies have been addressed to the FDA's satisfaction, the FDA will issue an approval letter. FDA approval authorizes commercial marketing of a drug or biologic product with specific prescribing information and for specific indications. As a condition of approval, the…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.